Related Experiment Video
Updated: Jan 3, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
XPO1 Gene Therapy Attenuates Cardiac Dysfunction in Rats with Chronic Induced Myocardial Infarction
María García-Manzanares1,2, Estefanía Tarazón2, Ana Ortega2
1Department of Animal Medicine and Surgery, Veterinary Faculty, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain.
Insights
Gene silencing of XPO1 using AAV9-shXPO1 partially restored heart function and reduced cardiac remodeling in a rat model of myocardial infarction. This approach shows promise for treating ischemic cardiomyopathy.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Gene Therapy
Background:
- Elevated XPO1 expression is linked to impaired left ventricular function in ischemic cardiomyopathy.
- Targeting XPO1 may offer a therapeutic strategy for heart failure.
Purpose of the Study:
- To investigate the efficacy of adeno-associated virus serotype 9 carrying short hairpin RNA against XPO1 (AAV9-shXPO1) in attenuating left ventricular dysfunction and remodeling post-myocardial infarction.
- To assess the impact of AAV9-shXPO1 on cardiac fibrosis and specific inflammatory markers.
Main Methods:
- Myocardial infarction was induced in Sprague-Dawley rats via coronary ligation.
- Rats received either AAV9-shXPO1 or a placebo AAV9-scramble treatment.
- Serial echocardiography assessed cardiac function and dimensions; cardiac tissue analysis evaluated fibrosis and gene/protein expression.
Main Results:
- AAV9-shXPO1 treatment partially recovered left ventricular fractional shortening and maintained left ventricular dimensions compared to placebo.
- Significant reduction in cardiac fibrosis and collagen content was observed in the AAV9-shXPO1 group.
- While XPO1 (Exportin 1) levels decreased, plasma levels of IL-6 and TNFR1 remained unchanged.
Conclusions:
- AAV9-shXPO1 administration effectively attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in a rat model.
- Gene silencing of XPO1 represents a potential therapeutic avenue for ischemic cardiomyopathy.
- Further research is needed to elucidate the precise mechanisms and clinical applicability.
Abstract:
Transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients. We hypothesized that treatment with AAV9-shXPO1 attenuates left ventricular dysfunction and remodeling in a myocardial infarction rat model. We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (n = 10), which received AAV9-shXPO1 (n = 5) or placebo AAV9-scramble (n = 5) treatment. Serial echocardiographic assessment was performed throughout the study. After myocardial infarction, AAV9-shXPO1-treated rats showed partial recovery of left ventricular fractional shortening (16.8 ± 2.8 vs 24.6 ± 4.1%, P < 0.05) and a maintained left ventricular dimension (6.17 ± 0.95 vs 4.70 ± 0.93 mm, P < 0.05), which was not observed in non-treated rats. Furthermore, lower levels of EXP-1 (P < 0.05) and lower collagen fibers and fibrosis in cardiac tissue were observed. However, no differences were found in the IL-6 or TNFR1 plasma levels of the myocardium of AAV9-shXPO1 rats. AAV9-shXPO1 administration attenuates cardiac dysfunction and remodeling in rats after myocardial infarction, producing the gene silencing of XPO1.
